Processa Pharmaceuticals Elects New Director
Ticker: PCSA · Form: 8-K · Filed: Jul 17, 2024 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $400,000, $50,000 b |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-of-directors, disclosure, officer-compensation
TL;DR
Processa Pharma adds a new director to the board, filing includes financial docs.
AI Summary
On July 16, 2024, Processa Pharmaceuticals, Inc. announced a change in its board of directors, with the election of Dr. David J. Gury to the board. The company also disclosed compensatory arrangements for certain officers and provided a Regulation FD disclosure. The filing also includes financial statements and exhibits.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns board appointments and routine disclosures, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- Dr. David J. Gury (person) — Newly elected director
- July 16, 2024 (date) — Date of earliest event reported
FAQ
Who was elected to the board of directors?
Dr. David J. Gury was elected to the board of directors.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is July 16, 2024.
What are the main items disclosed in this Form 8-K?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD disclosure, and financial statements and exhibits.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 45-1539785.
Filing Stats: 1,108 words · 4 min read · ~4 pages · Grade level 11.9 · Accepted 2024-07-17 08:00:22
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PCSA Nasdaq Ca
- $400,000 — d will be paid an annual base salary of $400,000 and will be eligible for a $50,000 base
- $50,000 b — of $400,000 and will be eligible for a $50,000 base salary increase upon the achievement
Filing Documents
- form8-k.htm (8-K) — 49KB
- ex10-1.htm (EX-10.1) — 96KB
- ex99-1.htm (EX-99.1) — 15KB
- ex10-1_001.jpg (GRAPHIC) — 30KB
- ex99-1_001.jpg (GRAPHIC) — 29KB
- 0001493152-24-028093.txt ( ) — 441KB
- pcsa-20240716.xsd (EX-101.SCH) — 3KB
- pcsa-20240716_lab.xml (EX-101.LAB) — 33KB
- pcsa-20240716_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROCESSA PHARMACEUTICALS, INC. Date: July 17, 2024 By: /s/ George Ng George Ng Chief Executive Officer